Want to Own OpenAI Stock Before Its IPO? Here Are 2 Ways Investors Can Buy Right Now.

OpenAI is reported to be targeting an IPO as early as Q4 2026, with a current valuation of $852 billion after revenue reportedly rose 225% to $13 billion in 2025 and is projected to reach $30 billion in 2026. The article highlights two ways to gain pre-IPO exposure: Ark Venture Fund, which holds 11% in OpenAI and 17% in SpaceX, and Microsoft, which owns a 27% stake in OpenAI plus a revenue-share agreement for 20% of sales through 2032. The piece is broadly constructive on OpenAI’s growth and monetization, but the market impact is limited because it is mostly an investing commentary article.

Analysis

The cleaner trade here is not the rumored OpenAI IPO itself, but the balance sheet and distribution rail around it. Microsoft is effectively monetizing OpenAI twice: mark-to-market upside on the equity stake plus a long-duration revenue stream whose value rises as OpenAI scales, which makes MSFT a quieter but more durable way to own the AI monetization curve. The second-order effect is that every step-up in OpenAI’s valuation tightens Microsoft’s strategic moat in enterprise AI, because competitors must now justify both product parity and economics against a partner that is already embedded in the profit pool.

ARKVX is a different animal: it is a liquidity wrapper around late-stage private-market beta, and the real risk is not just valuation compression but the mismatch between mark-to-model pricing and actual exitability. If IPO comps for OpenAI or Anthropic re-rate lower than private marks, the fund can gap down quickly while investors remain trapped inside an interval structure for up to a quarter. That illiquidity premium is currently being paid to own a concentrated basket of assets that are most sensitive to sentiment reset, especially in a market where AI capex and AI revenue are increasingly being scrutinized for payback discipline.

The market may be underestimating how much the OpenAI IPO could become a liquidity event for the entire private-AI ecosystem. A blockbuster listing would create a reference multiple for dozens of venture names, which is positive for holders like ARKVX, but it also increases scrutiny on adjacent names without OpenAI-scale engagement, particularly those relying on vague “AI optionality” narratives. Conversely, if the IPO is postponed or priced below expectations, MSFT likely absorbs the least damage because the core thesis shifts from multiple expansion to cash-flow participation.

The contrarian angle is that the best risk-adjusted expression may be MSFT into IPO timing, not because upside is capped, but because the downside is buffered by a huge non-AI business and recurring cloud/software earnings. The more speculative the private market gets, the more valuable that diversification becomes; in a drawdown, capital will likely rotate from standalone AI venture exposures into cash-generative platforms with embedded AI claims.

Key Decisions for Investors

• Long MSFT vs. ARKVX over the next 6-12 months: use MSFT as the preferred OpenAI proxy; expect superior downside capture with similar AI participation, especially if IPO pricing comes in below the current private mark.
• Buy MSFT Jan-2027 call spreads into IPO window: limited premium outlay for upside tied to OpenAI valuation and revenue-sharing optics; target 2:1 to 3:1 payoff if AI multiple expansion persists.
• Avoid initiating fresh ARKVX exposure unless you have a 12+ month horizon and can tolerate quarterly liquidity: the best-case upside is real, but the position is vulnerable to a mark-down if private AI multiples compress.
• If already long ARKVX, hedge with MSFT or QQQ puts around the IPO date: the fund’s concentrated private exposure makes it highly sensitive to a sentiment reversal; hedge ratio should scale to the 40% five-name concentration.
• Relative-value trade: long MSFT / short a basket of high-multiple private-AI proxies via public analogs or sector ETF hedges; the thesis is that monetization certainty will outperform narrative beta as the market shifts from enthusiasm to scrutiny.